An interventional study of ESAR treatment: Endograft + Heli-FX Endoanchor and FEVAR treatment : Fenestrated endograft in Aortic Aneurysm, Abdominal, sponsored by FCRE (Foundation for Cardiovascular Research and Education). Recruiting at 33 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by FCRE (Foundation for Cardiovascular Research and Education) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 122 studies in Aortic Aneurysm, Abdominal with a site in United States — 28 open to participants now, 34 under way, 1 of them phase 3. Aortic Aneurysm, Abdominal · United States.
Among the 122 studies in Aortic Aneurysm, Abdominal with a site in United States, this one is the 25th largest by planned enrollment of the 85 interventional ones that give a count, is one of 7 that started in 2021, is one of 64 with no phase, reaches primary completion later than 3 of the 33 other live ones, and was the 93rd registered.
467 studies on the registry are indexed under Aortic Aneurysm, Abdominal; 99 are open to participants now.
Browse Aortic Aneurysm, Abdominal studies →28 of the 122 studies in Aortic Aneurysm, Abdominal with a site in United States are open now. Recruiting first, the newest first:
University of Pennsylvania · Sites in United States
Ages 18+ · Healthy volunteers
Aiatella Oy · Sites in United States, Brazil
Ages 22+ · Healthy volunteers
Washington University School of Medicine · Sites in United States
Ages 18+ · Healthy volunteers
Steven Maximus · Sites in United States
Ages 18+
Cali Johnson · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 66 Aortic Aneurysm, Abdominal studies recruiting now, 52 (79%) set no upper age limit and 3 (5%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
122 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 8 · Phase 3 2 · Phase 4 4
First in 1998; this study’s year is marked. 7 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 204 is above the median of 66 across 228 interventional studies indexed under Aortic Aneurysm, Abdominal.
Median enrollment 94 across the 85 interventional studies, 210 across the 32 observational. Of the 74 that completed or were terminated, 39 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
63 of 122 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with FCRE (Foundation for Cardiovascular Research and Education) as lead sponsor.
FCRE (Foundation for Cardiovascular Research and Education) has 1 study filed under Aortic Aneurysm, Abdominal — fewer than ten, so there is no comparison to draw.
9 of the studies in Aortic Aneurysm, Abdominal with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04875429Cook Research IncorporatedZenith® Fenestrated+ Clinical Study | 2026-11 |
| NCT03446287Mayo ClinicClinical Outcomes of Patients Treated With Open Surgical Repair for Complex Aortic Aneurysms | 2026-12 |
| NCT05004051ViTAA Medical SolutionsViTAA Registry Pre- and Post-Operative Monitoring for Endovascular Aortic Aneurysm Repair and Serial Monitoring for AAA | 2026-12-31 |
| NCT07473102Washington University School of MedicinePET Imaging of MMP Activation in AAA: Clinical Component | 2027-03-31 |
| NCT06990048EndologixThe Long-Term EVAR Assessment and Follow-Up (LEAF) Study for the AFX2 System | 2027-05 |
Add all 9 to your calendar (.ics) → With an account.
Among the 122 studies in Aortic Aneurysm, Abdominal with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this randomized study is to compare the safety and performance of EndoVascular Aneurysm Repair with ESAR using Endurant + Heli-FX™ EndoAnchor™ system and FEVAR using customizable grafts from Cook (Zenith Fenestrated Graft) and Terumo (Fenestrated Anaconda Graft) for the treatment of aortic aneurysms with short aortic neck (4 to 15mm).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
CT Angiographic Inclusion Criteria
Exclusion Criteria:
Subject has an aneurysm that is:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Endovascular Aneurysm Repair + Heli-FX EndoAnchors
Device: ESAR treatment: Endograft + Heli-FX Endoanchor
Fenestrated EndoVascular Aneurysm Repair
Device: FEVAR treatment : Fenestrated endograft
ESAR treatment: Endurant II or Endurant IIs endograft + Heli-FX Endoanchor
Cook Zenith Fenestrated Graft or the Terumo Fenestrated Anaconda Graft
Effectiveness Endpoint - Technical Success
Composite of technical success at index procedure, and freedom from type IA or type III endoleak, freedom from aneurysm related mortality (ARM), and freedom from secondary reinterventions through 12 months post index procedure.
Time frame: through 12 months post-procedure
Safety Endpoint - Freedom from Major Adverse Events
Freedom from MAE through 30 days post index procedure. MAE defined as: All-Cause-Mortality, Bowel Ischemia, Myocardial Infraction, Procedural Blood Loss \> 1000cc, Access related complications, permanent paraplegia and paraparesis at 30 days, disabling stroke, respiratory failure, or renal complications
Time frame: through 30 days post-procedure
Total contrast volume (ml) at index procedure
Total contrast volume (mL) at index procedure
Time frame: at index procedure
Total fluoroscopy time (minutes) at index procedure
Total fluoroscopy time (minutes) at index procedure
Time frame: at index procedure
Duration (minutes) of index procedure
3\. Duration (minutes) of index procedure (time between initial skin access to final closure of the last artery access site)
Time frame: at index procedure
Adequate penetration of EndoAnchor implants as assessed by the Core Lab
Adequate penetration of EndoAnchor implants as assessed by the Core Lab
Time frame: at index procedure
Clinical success
7\. Clinical success defined as technical success + freedom from intra-operative death and freedom from type IA/III endoleak in the first post-op image within 30 days.
Time frame: through 30 days post-procedure
Visceral artery patency or occlusion at 1, 12, 24 and 36 months follow-up
Visceral artery patency or occlusion at 1, 12, 24 and 36 months follow-up
Time frame: through 1,12,24 and 36-months post-op
Freedom from type Ia and III endoleaks at 1, 12, 24 and 36 months follow-up
Freedom from type Ia and III endoleaks at 1, 12, 24 and 36 months follow-up
Time frame: through 1,12,24 and 36-months post-op
Freedom from aneurysm related secondary reinterventions at 1, 12, 24 and 36 months follow-up
Freedom from aneurysm related secondary reinterventions at 1, 12, 24 and 36 months follow-up
Time frame: through 1,12,24 and 36-months post-op
Freedom from aneurysm related mortality at 1, 12, 24 and 36 months follow-up
Freedom from aneurysm related mortality at 1, 12, 24 and 36 months follow-up
Time frame: through 1,12,24 and 36-months post-op
Freedom from stent graft migration (>10mm change from 1-month follow-up imaging) at 12, 24 and 36 months follow-up
Freedom from stent graft migration (\>10mm change from 1-month follow-up imaging) at 12, 24 and 36 months follow-up
Time frame: through 12,24 and 36-months post-op
Sac dynamics (>5mm change from 1-month follow-up imaging): increase, stable, decrease at 12, 24, and 36 months follow-up
Sac dynamics (\>5mm change from 1-month follow-up imaging): increase, stable, decrease at 12, 24, and 36 months follow-up
Time frame: through 12,24 and 36-months post-op
Freedom from conversion to open repair at 1, 12, 24 and 36 months follow-up
Freedom from conversion to open repair at 1, 12, 24 and 36 months follow-up
Time frame: through 1,12,24 and 36-months post-op
Freedom from AAA rupture at 1, 12, 24 and 36 months follow-up
Freedom from AAA rupture at 1, 12, 24 and 36 months follow-up
Time frame: through 1,12,24 and 36-months post-op
Overall SCI rate, include transient events at 1 and 12 months follow-up
Overall SCI rate, include transient events at 1 and 12 months follow-up
Time frame: through 1 and 12 months post-op
Freedom from aortic neck-related secondary interventions
reinterventions for Type IAa endoleak, migration of the proximal stent graft, and progression of disease in the infrarenal aortic neck; progression of disease is defined as enlargement of the infrarenal aortic neck compared to the first postprocedural CT scan, as measured by either diameter, surface and/or volume.
Time frame: at 1-, 12-, 24- and 36-months follow-up
Not enrolling at this site — choose another above.
Plan to share: No
No publications or documents are linked to this record.
Started May 2021 (actual). Primary completion is estimated for Jun 2026, 60 months after the start.
Of 51 non-industry interventional studies with no phase under Aortic Aneurysm, Abdominal, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 61. This study's planned 60 months is above that.
Counting every sponsor, half of 94 studies reached it within 43 months; a quarter within 23 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.